Conclusion
®, CLI, ulcers, pain, atherosclerotic PAD
LIMB ISCHEMIA, ULCERS, COMPLICATIONS
MSCs are being implemented as a therapeutic option for the treatment of complications resulting from atherosclerotic PAD. The angiogenic cell therapy using MSCs in atherosclerotic PAD patients in our study has shown long-term improvement in limb ischemia, leading to extension of amputation-free survival, improved quality of life, improvement in rest pain score, ABPI and ASP and healing of ulcers. Stempeucel® in a dose of 2 million cells/kg body weight administered intramuscularly in the calf muscle and injected locally around the ulcers is a feasible option to treat patients suffering from CLI due to atherosclerotic PAD as shown by this label extension study.